ESP Equity Partners, LLC
ESP Equity Partners, LLC is a private investment company working closely with experienced local management teams to acquire pharmaceutical and medical assets in targeted therapeutic areas.  ESP Equity is led by successful health care entrepreneurs with extensive international experience and a track record of sourcing undervalued products and executing deals in the United States, Asia and South America.

NewSpring Capital
NewSpring Capital, located in King of Prussia, PA and New York, NY, is a family of specific-purpose private equity funds, which includes: NewSpring Ventures, L.P., a venture capital fund providing equity capital to growth and expansion stage companies with a focus on information technology, business services and health care; Commerce Health Ventures, L.P., a venture capital fund focused on intermediate-and-late stage life science and health care companies; and NewSpring Mezzanine Capital, L.P., a regionally focused mezzanine debt fund that invests in information technology, business services, health care and specialty manufacturing.

Roxiticus Valley Life Sciences Fund, LP
RVLSF invests in early and expansion-stage healthcare and specialty pharma companies, and other companies in the life sciences industry. 

Roxiticus Ventures, LLC
Roxiticus Ventures, LLC provides business launch and financing services to EKR. 

For more information on investing in EKR please contact Richard DeSimone at 877-435-2524 ex144 or r.desimone@ekrtx.com

EKR BUSINESS MODEL

EKR Therapeutics is pursuing the acquisition of selected pharmaceutical products in the oncology supportive care market. EKR has already completed an acquisition for North American marketing and distribution rights for Gelclair^® for the treatment of mucositis, a common side effect that occurs in patients who undergo radiation and/or chemotherapy to treat their disease.

Due to the high incidence and wide scope of side effects from primary cancer therapies, patients suffer a variety of side effects.

‘Studies show that patients’ top priorities [when faced with a life-threatening or debilitating condition] are to be free of physical and psychological distress; to have some control over decisions about their health care; to avoid death-prolonging treatments; and to improve relationships with and reduce burden on their families.”

There are a wide variety of side effects that result from treatment, which in most cases involves radiation therapy, chemotherapy or a combination of the two. Some of the more common side effects of primary cancer treatment are:
 

• Skin reaction (hyperpigmentation, photosensitivity, itching, rash)

•  Blood flow and blood test abnormalities (bruising, blood clots, hypercalcemia, low blood counts)

• Bone complications (bone loss, bone pain, bone metastasis, fractures)

• Nutritional issues (mouth sores, dry mouth, weight loss, taste changes, weight loss/gain)

• Hair loss

• Nausea / Vomiting / Diarrhea

• Lung fibrosis

• Heart complications

• Mental / emotional problems (anxiety, depression, post-traumatic distress)

EKR intends to identify, acquire, market, distribute and eventually develop products which address the needs of patients as they look for supportive care during cancer treatment.

EKR will also seek selected cancer therapeutics in late stages of development or companies with promising pipelines in cancer treatment of support as possible acquisition targets.